AmgenvsMineralys Therapeutics

AMGN and MLYS stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

MLYS

Mineralys Therapeutics, Inc.

$13.66

Value $1.2B

-3.53%
MLYS's page

Amgen (AMGN) has a market value of $235B and Mineralys Therapeutics (MLYS) $1.2B. Over the last year, with dividends, AMGN moved +31.5% and MLYS -67.6%. Dividend yield: AMGN 2.31%, MLYS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    MLYS$1.2B

    AMGN is 194 times MLYS

  • Revenue, 12 months

    AMGN$38.9B

    MLYS–

  • Net income, 12 months

    AMGN$9.4B

    MLYS-$370M

  • Operating margin

    AMGN32.4%

    MLYS–

  • ROIC

    AMGN16.2%

    MLYS-20.8%

    37.0 points apart

  • P/E

    AMGN25.0

    MLYS–

  • Dividend yield

    AMGN2.3%

    MLYS0.0%

    2.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+79.3%

MLYS+112.4%

200400600202420252026
Returns by period
PeriodAMGNWith dividendsMLYSWith dividends
1 year since November 19, 2025+31.5%Price +27.2%-67.6%Price -67.6%
3 years since November 20, 2023+79.2%+21.5% a yearPrice +64.2%+112.4%+28.6% a yearPrice +112.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenMLYSMineralys Therapeutics

Valuation

AMGNMLYS
Valuation
Price$435.64$13.66
Market value$235B$1.2B
Enterprise value (EV)$276B$585M
P/E25.0–
P/E, 5-year median23.0–
P/B16.42.4
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNMLYS
Results and growth
Revenue, 12 months$38.9B–
Net income, 12 months$9.4B-$370M
Free cash flow, 12 months$9.6B-$153M
Earnings per share, 12 months$17.25-$4.31
Revenue growth, year on year10.0%–
Revenue growth a year, past+7.6%over 5 years–
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNMLYS
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%–
Net margin24.1%–
ROIC16.2%-20.8%
ROE87.8%-63.4%

Balance sheet

AMGNMLYS
Balance sheet
Cash$13.2B$625M
Total debt$54.0B$100.0K
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNMLYS
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or MLYS

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Mineralys Therapeutics?

By market value, Amgen ($235B) is about 194.1 times Mineralys Therapeutics ($1.2B), at today's prices.

How did AMGN and MLYS stock do over the last 3 years?

Since November 20, 2023, AMGN's price moved +64.2% and MLYS's +112.4%. With dividends: AMGN +79.2% (+21.5% a year), MLYS +112.4% (+28.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or MLYS?

The dividend yield at today's price is 2.31% for Amgen and none for Mineralys Therapeutics. Over the last twelve months they paid $10.08 and – per share.

Which is the better investment, Amgen or Mineralys Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.